INDEMNIFICATION AGREEMENTIndemnification Agreement • April 5th, 2019 • Trevi Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is made and entered into as of , 201 between Trevi Therapeutics, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”).
Trevi Therapeutics, Inc. STOCK OPTION AGREEMENTStock Option Agreement • April 5th, 2019 • Trevi Therapeutics, Inc. • Pharmaceutical preparations
This option satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.
TREVI THERAPEUTICS, INC. SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTRights Agreement • April 5th, 2019 • Trevi Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT is made as of the 14th day of July, 2017, by and among Trevi Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor,” and any Additional Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with Section 6.9 hereof.
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. EXCLUSIVE LICENSE AGREEMENT BY...Exclusive License Agreement • April 5th, 2019 • Trevi Therapeutics, Inc. • Pharmaceutical preparations • Pennsylvania
This Exclusive License Agreement is entered into this 13th day of May, 2011 (the “Effective Date”), by and between Trevi Therapeutics, Inc,, a Delaware company, with principal offices located at 52 Charter Ridge Drive, Sandy Hook, CT 06482 (“Trevi”) and Penwest Pharmaceuticals Co,, a Washington corporation, with principal offices located at 100 Endo Boulevard, Chadds Ford, PA 19317 (“Penwest”). Each of Trevi and Penwest may be referred to, individually, as a “Party”, and, collectively, as the “Parties”.
TREVI THERAPEUTICS, INC. EMPLOYMENT AGREEMENTEmployment Agreement • April 5th, 2019 • Trevi Therapeutics, Inc. • Pharmaceutical preparations • New York
This EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into by and between Trevi Therapeutics, Inc., a Delaware corporation (the “Company”) and Jennifer L. Good (the “Executive”) as of this 4th day of December, 2012.
ContractTrevi Therapeutics, Inc. • April 5th, 2019 • Pharmaceutical preparations
INDEFINITE TERM EMPLOYMENT CONTRACT BETWEEN: Trevi Therapeutics, Inc. a foreign company having no place of business in France, whose registered office is located 195 Church Street, 14th floor, 06510 New Haven (CT/ USA), duly represented by Jennifer Good, in her capacity as President & CEO, Hereinafter referred to as the “Company” or “Employer” or “Trevi”, ONE THE ONE HAND AND: Mister Yann Mazabraud, born on 11/11/72 Maubeuge in residing at 15, avenue Aristide Briand 78360 Montesson (France) whose social security identification number is Hereinafter referred to as the ‘“Employee” or “Mr Mazabraud”, ON THE OTHER HAND. Together hereafter referred to as the “Parties”. IT HAS BEEN AGREED AND DECIDED AS FOLLOWS: 1/ Start date—Job Title—Collective bargaining agreement—Trial period Trevi hereby employs Mr Mazabraud as from September 1st, 2018 subject to the satisfactory results of the medical check-up. M. Mazabraud is hired pursuant to an indefinite term employment contract as Chief Commercial
First Amendment to LeaseLease • April 5th, 2019 • Trevi Therapeutics, Inc. • Pharmaceutical preparations
THIS FIRST AMENDMENT TO LEASE (“First Amendment”) dated December 5, 2017, by and between 195 Church Street Associates, LLC, a Connecticut limited liability corporation (“Landlord”) and Trevi Therapeutics, Inc. (“Tenant”).
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. EXCLUSIVE LICENSE AGREEMENT...Exclusive License Agreement • April 5th, 2019 • Trevi Therapeutics, Inc. • Pharmaceutical preparations • New Jersey
For the sake of clarity, each Milestone Payment is payable no more than once and only with respect to the first achievement of the relevant Milestone Event for a Licensed Product. In no event shall all Milestone Payments, in the aggregate, total more than $62,500. In no event shall any Milestone Payment be payable after the end of the expiration of the last Valid Claim of the Patent Rights.
